Endocrine resistance in breast cancer: Molecular pathways and rational development of targeted therapies

Ryan P. Roop, Cynthia X. Ma

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations

Abstract

Endocrine resistance presents a major challenge in the management of estrogen receptor (ER)-positive breast cancer and is an area under intense investigation. Although the underlying mechanism is still poorly understood, many studies point towards the 'cross-talk' between ER and growth factor receptor signaling pathways as the key in the development of estrogen-independent growth in breast cancer. This review aims to provide the reader our current understanding of various molecular pathways that mediate endocrine resistance and that are being evaluated as therapeutic targets for ER-positive breast cancer. While most of the agents that target these pathways have only been tested in Phase I or small Phase II trials, some have shown encouraging results. A critical issue that remains is the development of research strategies and clinical trials that take into account the molecular heterogeneity of ER-positive breast cancer.

Original languageEnglish
Pages (from-to)273-292
Number of pages20
JournalFuture Oncology
Volume8
Issue number3
DOIs
StatePublished - Mar 1 2012

Keywords

  • breast cancer
  • endocrine resistance
  • growth factor
  • targeted therapy

Fingerprint

Dive into the research topics of 'Endocrine resistance in breast cancer: Molecular pathways and rational development of targeted therapies'. Together they form a unique fingerprint.

Cite this